Author + information
Because,dyslipidemia,inflammation and hypercoagulation are the major risk factors for cardiovascular diseases we examined the Effects of CoQ10 supplementation on serum lipoprotein, Il-6, ICAM-1 and plasma fibrinogen in hyperlipidemic patients with myocard infarction. In a double blind placebo controled clinical trial, 52 hyperlipidemic patients with myocard infarction and age range of 35-70 years were randomly allocated to receive daily 200 mg coQ10 or placebo for 3 months. Fasting blood, Physical activity and daily dietary intake were obtained at beginning and end of 3 months. SPSS version 18 were used for statistical analysis. At the end of study in CoQ10 group,There were significant decrease in total cholesterol (TC), Triglyceride (TG), LDL-c, LDL-c/HDL-c and TC/HDL-c (p<0.05), IL-6 (p<0.001) and ICAM-1 (p<0.001) and significant increase in HDL-c (p<0.05) compare to beginning of study. At the end of study there were significant decrease in LDL-c/HDL-c (p<0.05), TC/HDL-c (p<0.05), IL-6 (p<0.001), ICAM-1 (P<0.001) and significant increase in HDL-c (p<0.05) compare to placebo group.We can conclude that 200 mg daily CoQ10 for 3 months may have favorite effects on serum lipoproteins and inflammation indicators but no effect on fibrinogen and may be benefical in myocardial infarction patients.